Table 1 Characteristics of patients in the included studies
Author, year | Number | Cell type | Cell dose | Course of treatment (months) |
|---|---|---|---|---|
Amit N Patel, 2016 [24] | 66 | Ixmyelocel-T+BMA | 0.8 ml | 12 |
60 | Placebo+BMA | 0.8 ml | 12 | |
Amit N. Patel, 2005 [11] | 10 | Stem cells (CD34+) | 250 ml | 6 |
10 | Own plasma | 30 ml | 6 | |
Amit N. Patel, 2015 [12] | 24 | BMAC infusion | 240 ml | 12 |
6 | Medical standard of care | – | 12 | |
Anders Bruun Mathiasen, 2015 [13] | 40 | MSCs | 0.2 ml | 6 |
20 | PBS | 0.2 ml | 6 | |
Emerson C. Perin, 2011 [6] | 20 | ABMMNC | 3 ml | 6 |
10 | Simulated mock injection | – | 6 | |
Emerson C. Perin, 2012 [2] | 10 | ALDHbr | 3 ml | 6 |
10 | 5% Albumin | 3 ml | 6 | |
Emerson C. Perin, 2003 [7] | 14 | ABMMNC | 50 ml | 2 |
7 | Placebo | – | 4 | |
Jozef Bartunek, 2013 [3] | 32 | Bone marrow stem cells | 50 × 106 | 24 |
15 | Standard of care | – | 24 | |
Shengshou Hu, 2011 [8] | 31 | CABG+BMMNC | 60 ml | 6 |
29 | CABG | 10 ml | 6 | |
Zhi Qi, 2015 [25] | 24 | CABG+BMMNC | 60 ml | 12 |
18 | CABG | 10 ml | 12 | |
Evgeny Pokushalov, 2010 [26] | 49 | ABMMNC+Medical therapy | 41 ± 16 × 106 | 12 |
31 | Medical therapy | – |  | |
Nabil Dib, 2009 [27] | 12 | AMT+MMT | 2.5 × 107 | 12 |
11 | MMT | – |  | |
Philippe Menasché, 2008 [29] | 30 | Myoblast | 8 × 108 | 6 |
34 | Placebo | – |  | |
Qiang Zhao, 2008 [28] | 18 | BMMNC | An average of 6.59 × 108 ± 5.12 × 108 | 6 |
18 | Saline | – |  |